Artelo Biosciences, Inc. - Common Stock (ARTL)
9.5000
-3.7700 (-28.41%)
NASDAQ · Last Trade: Jul 1st, 6:55 PM EDT
Detailed Quote
Previous Close | 13.27 |
---|---|
Open | 11.12 |
Bid | 9.580 |
Ask | 9.850 |
Day's Range | 9.110 - 11.81 |
52 Week Range | 4.918 - 25.58 |
Volume | 532,689 |
Market Cap | 31.17M |
PE Ratio (TTM) | -4.241 |
EPS (TTM) | -2.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,361,997 |
Chart
About Artelo Biosciences, Inc. - Common Stock (ARTL)
Artelo Biosciences Inc is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology and pain management. The company is dedicated to advancing its proprietary drug candidates that target the endocannabinoid system, aiming to improve patients’ quality of life and treatment outcomes. Through its research and development efforts, Artelo seeks to harness the therapeutic potential of cannabinoids and related compounds, striving to bring new solutions to difficult-to-treat conditions. Read More
News & Press Releases
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · July 1, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 1, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via Chartmill · July 1, 2025
Via Benzinga · July 1, 2025
Via Benzinga · July 1, 2025
Synergy CHC Corp. (NASDAQ: SNYR), a rising consumer staple health company, has announced a wave of major expansion throughout North American for its FOCUSfactor® supplements and functional beverage brands, across mass, grocery, convenience, and wholesale channels. Functional Beverage Momentum
Via AB Newswire · June 30, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · June 30, 2025
The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.
Via Stocktwits · June 30, 2025
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
Via Benzinga · June 30, 2025
Via Benzinga · June 30, 2025
Via Benzinga · June 11, 2025
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies.
Via Benzinga · April 28, 2025
Via Benzinga · April 23, 2025
Via Benzinga · April 14, 2025

Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.
Via Benzinga · January 13, 2025

ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024

ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 25, 2024

Via Benzinga · March 6, 2024